After four weeks of allantoin administration, SREBP1c significantly decreased in the NASH+allantoin group compared with the NASH group (8.42± 0.06vs 24.85±0.06, P<0.001). Here, SREBF1 is linked to metabolic dysfunction-associated steatohepatitis.